Related Experiment Video
Updated: Aug 23, 2025
09:29
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
884
Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure
Y U Horiuchi1, Nicholas Wettersten2, Dirk J VAN Veldhuisen3
1Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Journal of Cardiac Failure
|November 4, 2022
Summary
Higher galectin-3 levels in acute heart failure (AHF) patients indicate kidney and heart injury. This biomarker predicts worse outcomes, including increased mortality risk.
Area of Science:
- Cardiology
- Nephrology
- Biomarker Research
Background:
- Galectin-3 is a known biomarker for inflammation and fibrosis.
- It has been linked to renal and myocardial damage in acute heart failure (AHF).
Purpose of the Study:
- To investigate the association between galectin-3 levels and renal/myocardial injury in AHF patients.
- To evaluate galectin-3 as a predictor of outcomes in AHF.
Main Methods:
- Retrospective analysis of 790 AHF patients from the AKINESIS study.
- Assessed acute kidney injury (KDIGO), renal tubular damage (uNGAL), and myocardial injury (hs-cTnI).
- Used multivariable regression and Cox analysis to determine associations with outcomes.
Main Results:
- Elevated galectin-3 (> 25.9 ng/mL) correlated with higher rates of acute kidney injury, renal tubular damage, and myocardial injury.
- Galectin-3 showed negative association with estimated glomerular filtration rate and positive association with uNGAL and hs-cTnI.
- Higher galectin-3 predicted in-hospital mortality and was associated with increased 1-year mortality risk, particularly death alone after adjustment.
Conclusions:
- In AHF patients, elevated galectin-3 is associated with renal dysfunction, renal tubular damage, and myocardial injury.
- Higher galectin-3 levels serve as a predictor of adverse outcomes, including mortality.
Related Concept Videos
01:29Acute Kidney Injury III: Clinical Manifestations
67
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
67
01:29Acute Kidney Injury II: Pathophysiology
53
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
53
01:22Acute Kidney Injury I: Introduction
59
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
59
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
53
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
53
01:30Acute Coronary Syndrome III: Diagnostic Studies
20
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
485
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
485